<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03944356</url>
  </required_header>
  <id_info>
    <org_study_id>EUMR-18001</org_study_id>
    <nct_id>NCT03944356</nct_id>
  </id_info>
  <brief_title>BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients</brief_title>
  <acronym>Combi-EU</acronym>
  <official_title>BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients in the Adjuvant Setting: a Non-interventional Observatory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EuMelaReg gGmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EuMelaReg gGmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adjuvant therapy with dabrafenib plus trametinib in melanoma was approved in 2018 by the EMA&#xD;
      (EUropean Medicines Agency).&#xD;
&#xD;
      The purpose of this non-interventional study is to assess the usage of adjuvant dabrafenib&#xD;
      and trametinib in clinical practice, where the patient population may differ from study&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melanoma is a disease of significant metastatic potential if not detected very early.&#xD;
      Oncogenic mutations in BRAF (B-Raf proto-oncogene, serine/threonine kinase) are found in&#xD;
      approximately 40% of melanomas and result in constitutive activation of the MAPK&#xD;
      (Mitogen-Activated Protein Kinase) pathway.&#xD;
&#xD;
      Treatment with the BRAF inhibitor dabrafenib plus the MEK (Mitogen-activated protein kinase&#xD;
      kinase) inhibitor trametinib showed improved overall survival in patients with unresectable&#xD;
      or metastatic BRAF V600E/K-mutant melanoma (COMBI-d and COMBI-v studies). In an adjuvant&#xD;
      setting treatment with dabrafenib and trametinib significantly reduced the risk of melanoma&#xD;
      recurrence in patients with high-risk, stage III BRAF V600-mutant melanoma, with improvements&#xD;
      in OS (Overall Survival), DMFS (Distant Metastasis Free Survival), and FFR (Freedom From&#xD;
      Relaps) (COMBI-AD study). Based on these results, adjuvant dabrafenib plus trametinib therapy&#xD;
      was approved in 2018 by the EMA.&#xD;
&#xD;
      Compared to the metastatic situation, issues of compliance and treatment adherence may be&#xD;
      more relevant in adjuvant treatments, as patients are free of disease and potentially cured&#xD;
      even without adjuvant treatment. As the routine administration of drugs including dosing,&#xD;
      treatment interruptions, and early termination in clinical practice may vary from procedures&#xD;
      defined in clinical trials, this study aims to assess the usage of adjuvant dabrafenib and&#xD;
      trametinib in the routine clinical setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Median time on treatment</measure>
    <time_frame>Date of first dose up to 12 months</time_frame>
    <description>Median time on adjuvant dabrafenib + trametinib treatment defined as the interval between start of treatment and permanent discontinuation of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Permanent study drug discontinuation due to any reason</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Rate of permanent study drug discontinuation due to any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent study drug discontinuation due to adverse drug reactions</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Rate of permanent study drug discontinuation due to adverse drug reactions (ADRs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pyrexia and related symptoms</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Occurrence of pyrexia and related symptoms, listing the grade, number of episodes, and time to resolution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reaction management: pyrexia</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Type of adverse drug reaction (ADR) management applied for pyrexia and correlation with occurrence/persistence of pyrexia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reactions in Follow-up</measure>
    <time_frame>From date of first treatment until the date of treatment end plus 3 months of follow-up, assessed up to 15 months</time_frame>
    <description>ADRs persisting/emerging up to 3 months post-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Over the course of treatment plus 3 months safety follow up, assessed up to 15 months</time_frame>
    <description>Assessment of health-related quality of life (HRQoL), measured by the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC-QLQ-C30).&#xD;
The EORTC QLQ-C30 consists of the folowing scales, with each dimension specifying five levels of severity [not at all (level 1), a little (level 2), quite a bit (level 3), very much (level 4)]:&#xD;
functional scales (Physical, Role, Cognitive, Emotional, Social Functioning)&#xD;
symptom scales (Fatigue, Pain and Nausea/Vomiting)&#xD;
single item scales (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).&#xD;
Additionally the Global Health Status and QoL scales are incorporated, specifying on a scale from 1 (very poor) to 7 (excellent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Relapse free survival (RFS) time and rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis free survival time</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Distant metastasis free survival (DMFS) time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis free survival rate</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Distant metastasis free survival (DMFS) rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Overall survival (OS) time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Overall survival (OS) rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on treatment and efficacy endpoints</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Correlation between time on treatment and efficacy endpoints (RFS, DMFS, OS).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib and Trametinib</intervention_name>
    <description>Dabrafenib and trametinib treatment under routine conditions according to the applying SmPC.</description>
    <other_name>Tafinlar and Mekinist</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with complete surgical resection of histologically confirmed AJCC (8th&#xD;
        edition) clinical stage III (IIIA, IIIB, IIIC, IIID) BRAF V600-mutated cutaneous melanoma&#xD;
        who are planned to be treated or who already started treatment no longer than 4 weeks prior&#xD;
        to study inclusion with dabrafenib and trametinib under routine conditions according to the&#xD;
        applying SmPC.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with complete surgical resection of histologically confirmed AJCC (American&#xD;
             Joint Committee on Cancer) (8th edition) clinical stage III (IIIA, IIIB, IIIC, IIID)&#xD;
             melanoma, for whom a decision for adjuvant treatment with dabrafenib and trametinib&#xD;
             has been made before entering the study.&#xD;
&#xD;
          -  V600E/K mutation-positive cutaneous melanoma&#xD;
&#xD;
          -  Adjuvant treatment with combination therapy of Dabrafenib (Tafinlar®) and Trametinib&#xD;
             (Mekinist®) as indicated in the SmPC (Summary of Product Characteristics) and by&#xD;
             prescription, that has been started no longer that 4 weeks before inclusion of the&#xD;
             patient into the study or which will be initiated directly after inclusion&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of basic demographics and staging information&#xD;
&#xD;
          -  Current or planned participation within a clinical trial. The participation in a&#xD;
             follow-up phase of a clinical trial without active intervention is allowed.&#xD;
&#xD;
          -  Current or planned treatment of another tumor disease except keratoacanthoma, squamous&#xD;
             cell or basal cell carcinoma of the skin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Alexandra Hansen</last_name>
    <phone>+49 3037026901</phone>
    <email>alexandra.hansen@eumelareg.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Elbe Kliniken Stade - Buxtehude GmbH</name>
      <address>
        <city>Buxtehude</city>
        <state>Niedersachsen</state>
        <zip>21614</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Mohr, Dr.</last_name>
      <phone>+49 41617036217</phone>
      <email>Peter.Mohr@elbekliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Schadendorf, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Kiel, Klinik für Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Micheal Weichenthal, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Welzel, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bayreuth GmbH</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Kiani, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologisches Versorgungszentrum Friedrichshain</name>
      <address>
        <city>Berlin</city>
        <zip>10407</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert Lebahn, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Susok, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen Mitte gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kjell Kaune, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremerhaven Reinkenheide gGmbH</name>
      <address>
        <city>Bremerhaven</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Sachse, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DRK Krankenhaus Chemnitz Rabenstein</name>
      <address>
        <city>Chemnitz</city>
        <zip>09117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabian Ziller, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt GmbH</name>
      <address>
        <city>Darmstadt</city>
        <zip>64297</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Podda, PD Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Dessau</name>
      <address>
        <city>Dessau</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietrich Trebing, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund gGmbH</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pia Duecker, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Wollina, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedegund Meier, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS St. Johannes Klinik Duisburg</name>
      <address>
        <city>Duisburg</city>
        <zip>47166</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris Kamphausen, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätskliniken Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman-Philipp Hoff, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Erfurt</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Herbst, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Heppt, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera GmbH</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Kaatz, PD Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Arnold, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Halle</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose KC Moritz, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoffer Gebhardt, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imke Grimmelmann, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Hassel, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus-Detlev Klemke, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan C Simon, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigshafen gGmbH</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar Dippel, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23568</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Terheyden, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mareike Alter, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen Utikal, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Stader, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Max Schlaak, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fachklinik Hornheide</name>
      <address>
        <city>Münster</city>
        <zip>48157</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Schulze, PD Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Debus, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios St. Elisabeth Klinik Oberhausen</name>
      <address>
        <city>Oberhausen</city>
        <zip>46045</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Harzklinikum Dorothea Christiane Erxleben GmbH</name>
      <address>
        <city>Quedlinburg</city>
        <zip>06484</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Ulrich, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Haferkamp, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Kliniken Schwerin</name>
      <address>
        <city>Schwerin</city>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaston Schley, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike MB Leiter-Stoeppke, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anca Sindrilaru, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrich Wesselmann, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

